Trending Topic

Breast Cancer
29 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Endocrine therapy (ET) has changed the natural history of hormone receptor-positive (HR+) breast cancer (BC) and is the cornerstone of the treatment of HR+ BC. There are several ETs approved for the treatment of BC, including selective oestrogen receptor modulators (SERMs; tamoxifen), aromatase inhibitors (AIs; anastrazole, letrozole and exemestane) and selective oestrogen receptor degraders (SERDs; fulvestrant […]

Stephen B Williams, ASCO 2021: TAR-200 in Combination with Cetrelimab in Muscle-invasive Urothelial Carcinoma of the Bladder

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Jul 13th 2021

touchONCOLOGY joins Professor Stephen B Williams (Chief, Division of Urology, Professor of Urology and Radiology, Division of Urology, The University of Texas Medical Branch, Galveston, TX, USA) at ASCO 2021 to discuss the efficacy of TAR-200 in combination with cetrelimab in participants with muscle-invasive urothelial carcinoma of the bladder.

The abstract ‘A phase 3, multicenter, randomized study evaluating the efficacy of TAR-200 in combination with cetrelimab versus concurrent chemoradiotherapy in participants with muscle-invasive urothelial carcinoma of the bladder (NCT04658862)’ (abstract number TPS4586) was presented at the 2021 ASCO Annual Meeting.

DOI: 10.1200/JCO.2021.39.15_suppl.TPS4586 Journal of Clinical Oncology 39, no. 15_suppl

Questions
1. What risks are associated with radical cystectomy in the treatment of muscle-invasive bladder cancer? (00:35-01:43)

2. Could you tell us a little about the TAR-200 drug delivery system and the rationale for combining its use with systemic cetrelimab in muscle-invasive bladder cancer? (01:43-02:30)

3. What are the aims and design of the SunRISe-2 study? (02:30-03:24)

4. What are the eligibility criteria of the study? (03:24-04:44)

5. What are the study endpoints? (04:44-05:35)

6. When are data expected to be presented? (05:35-07:05)

Disclosures: Consultant for Photocure and UroToday; travel fees and advisory board for Janssen.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Helen Fowler.

Filmed in coverage of the 2021 ASCO Annual Meeting.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied

This Functionality is for
Members Only

Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

Close Popup